Target type: biologicalprocess
The compaction of chromatin into a conformation that is refactory to transcription but that be converted to euchromatin and allow transcription in specific contexts. These can be temporal (e.g., developmental states or specific cell-cycle stages), spatial (e.g., nuclear localization changes from the center to the periphery or vice versa due to exogenous factors/signals), or parental/heritable (e.g., monoallelic gene expression). [PMID:17936700]
Facultative heterochromatin is a dynamic and reversible form of chromatin that can transition between euchromatin (active) and heterochromatin (inactive) states. This dynamic nature allows for flexible gene regulation in response to cellular needs and environmental cues.
Here's a detailed breakdown of the biological process of facultative heterochromatin formation:
1. **Initiation:** The process often begins with specific signals, like developmental cues, environmental stress, or cell cycle checkpoints. These signals trigger the recruitment of proteins that modify the chromatin structure.
2. **Histone Modifications:** Key players in this process are histone modifying enzymes, particularly histone deacetylases (HDACs) and histone methyltransferases (HMTs).
- HDACs remove acetyl groups from histone tails, leading to a more condensed chromatin structure.
- HMTs add methyl groups to histone tails, particularly lysine residues. Different methylation patterns can either promote or repress gene expression.
3. **Chromatin Remodeling:** Specialized protein complexes, known as chromatin remodelers, can alter the position of nucleosomes, the basic unit of chromatin. This can expose or hide DNA sequences, influencing transcription.
4. **Recruitment of Repressive Factors:** As chromatin condenses, it attracts proteins that further promote gene silencing. These include:
- Polycomb group proteins (PcG): They establish and maintain repressive chromatin domains by adding repressive histone modifications.
- HP1 proteins: They bind to specific histone methylation marks and promote heterochromatin formation.
5. **Silencing of Gene Expression:** The combination of histone modifications, chromatin remodeling, and repressive factor binding leads to the inactivation of genes within the facultative heterochromatin region. This can occur through various mechanisms, including:
- Blockage of transcription factor binding.
- Inhibition of RNA polymerase recruitment.
- Reduced accessibility of DNA for replication or repair.
**Key Points:**
- **Reversibility:** Facultative heterochromatin is dynamic and can be reversed through the action of opposing enzymes and factors.
- **Context-dependent:** The formation of facultative heterochromatin is highly dependent on cellular context and signaling pathways.
- **Developmental and Cellular Roles:** This process is crucial for various cellular functions, including:
- Developmental gene regulation: It ensures the proper expression of genes during development.
- Cell-type specific gene expression: It helps define the unique characteristics of different cell types.
- Cellular responses to stress: It can be used to shut down genes that are not essential during stressful conditions.
- X chromosome inactivation: This process is crucial for dosage compensation in females, where one X chromosome is silenced in each cell.
In summary, facultative heterochromatin is a highly regulated process that plays a vital role in controlling gene expression and cellular function. It involves a complex interplay of histone modifications, chromatin remodeling, and the recruitment of repressive factors.'
"
Protein | Definition | Taxonomy |
---|---|---|
Histone-lysine N-methyltransferase EZH2 | A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910] | Homo sapiens (human) |
Polycomb protein SUZ12 | A polycomb protein SUZ12 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15022] | Homo sapiens (human) |
Lysine-specific demethylase 5A | A lysine-specific demethylase 5A that is encoded in the genome of human. [PRO:DNx, UniProtKB:P29375] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
4-hydroxybenzoic acid hydrazide | 4-hydroxybenzohydrazide : A carbohydrazide obtained by formal condensation of the carboxy group of 4-hydroxybenzoic acid with hydrazine. 4-hydroxybenzoic acid hydrazide: metabolite of nifuroxazide | carbohydrazide; phenols | |
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
2,4-pyridinedicarboxylic acid | lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4. | pyridinedicarboxylic acid | |
daminozide | daminozide: induces tumors | straight-chain fatty acid | |
3-deazaneplanocin | 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist | ||
tanshinone | tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent | abietane diterpenoid | anticoronaviral agent |
di-n-desethylamiodarone | di-N-desethylamiodarone: amiodarone metabolite in dogs; structure given in first source | ||
przewaquinone d | przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D | ||
tanshinone ii a | tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source | abietane diterpenoid | |
deferasirox | deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions. Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA. | benzoic acids; monocarboxylic acid; phenols; triazoles | iron chelator |
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
6-ethyl-2,5-dimethyl-7-oxo-1H-pyrazolo[1,5-a]pyrimidine-3-carbonitrile | pyrazolopyrimidine | ||
oxalylglycine | N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes. oxalylglycine: structure given in first source | amino dicarboxylic acid; N-acylglycine | EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor |
geldanamycin | 1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound | antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor | |
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group. | 1,4-benzoquinones; ansamycin; carbamate ester; secondary amino compound; tertiary amino compound | Hsp90 inhibitor |
tanespimycin | CP 127374: analog of herbimycin A | 1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound | antineoplastic agent; apoptosis inducer; Hsp90 inhibitor |
(5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone | aromatic carboxylic acid; pyridinemonocarboxylic acid | ||
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid | organonitrogen heterocyclic compound | ||
entecavir | benzamides; N-acylpiperidine | ||
epz005687 | EPZ005687: inhibits EZH2 protein; structure in first source | indazoles | |
epz-6438 | tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity | ||
gsk-2816126 | GSK-2816126: inhibits EZH2 methyltransferase; structure in first source | piperazines; pyridines | |
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | (R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitor | indolecarboxamide |